

Tarpeyo (budesonide delayed release capsules)

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Tarpeyo (budesonide delayed release capsules)	1
Summary	1
Definitions	2
Clinical Indications	3
Medical Necessity Criteria for Clinical Review	3
General Medical Necessity Criteria	3
Experimental or Investigational / Not Medically Necessary	5
References	5
Appendix A	6
Clinical Guideline Revision / History Information	7

Summary

IgA nephropathy, also known as Berger's disease, is a type of kidney disease that is caused by the accumulation of immunoglobulin A (IgA) in the kidneys. It is a chronic, progressive disease that can lead to kidney failure if left untreated.

The exact cause of IgA nephropathy is not fully understood, but it is believed to be related to an abnormal immune response that causes the body to produce aberrant galactose-deficient IgA1, which then accumulates in the kidneys. This accumulation can lead to inflammation and damage to the small blood vessels in the kidneys, leading to a decrease in kidney function over time.

The most common symptom of IgA nephropathy is blood in the urine, which may be visible or only detected through laboratory tests. Other symptoms may include proteinuria (excess protein in the urine), high blood pressure, swelling of the hands and feet, decreased kidney function and fatigue. However, some people with IgA nephropathy may have no symptoms at all.

Diagnosis of IgA nephropathy typically involves a combination of urine tests and blood tests and is confirmed via kidney biopsy. Treatment options depend on the severity of the disease and may include medications to control blood pressure and reduce inflammation (i.e., “supportive care”), as well as dietary and lifestyle changes to help protect the kidneys. In high-risk patients (i.e, proteinuria ≥ 1 g/day despite at least 3-6 months of optimized supportive care), immunosuppressive therapy is recommended (e.g., systemic glucocorticoids, targeted-release budesonide, mycophenolate mofetil, calcineurin inhibitors [cyclosporine, tacrolimus], rituximab, cyclophosphamide, azothiaprime, leflunomide, hydroxychloroquine).

In some cases, IgA nephropathy may progress to end-stage renal disease, which requires dialysis or kidney transplant. However, early diagnosis and treatment can help slow the progression of the disease and preserve kidney function. Tarpeyo (budesonide delayed release capsules) is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. Tarpeyo (budesonide delayed release capsules) approval was based on the findings of the NeflgArd study, which found that in participants on a stable dose of maximally tolerated renin-angiotensin-System (RAS) inhibitor therapy in the Tarpeyo arm had a significant reduction in urine-protein-to-creatinine ratio (UPCR) and significantly lower decline in renal function (measured by estimate glomerular filtration rate[eGFR]). The recommended dose of Tarpeyo (budesonide delayed release capsules) is 16 mg administered orally once daily for a duration of 9 months; this is followed by a reduced dose of 8 mg once daily for the last 2 weeks of (whether discontinued before 9 months or after the 9-month course).

Definitions

“Angiotensin-converting enzyme (ACE) inhibitor” is a class of medications that lowers blood pressure by relaxing blood vessels.

“Angiotensin II receptor blocker (ARB)” is a class of medications similar to ACE inhibitors, that lowers blood pressure.

“C3 glomerular nephropathy” is a set of rare kidney diseases caused by a disorder of the complement system, part of the body’s immune system.

“Diabetic nephropathy” is a long-term complication of diabetes, resulting in damage to the kidneys, reduction in kidney function and can lead to chronic kidney disease or end-stage renal disease.

"Dialysis" is a procedure that removes waste and fluid from the blood when the kidneys stop working properly.

"Estimated Glomerular Filtration Rate (eGFR)" is a measure of how well the kidneys are working.

"Glomerulopathies" are a group of kidney diseases that affect the tiny blood vessels that filter blood in the kidney.

"Immunoglobulin A nephropathy (IgAN)" is a disease of the kidney that occurs when an antibody called immunoglobulin A (IgA) builds up in the kidney.

"Immunosuppressives" are any agent aimed at reducing the body's immune response, which may be used to treat conditions characterized by overactive immune systems, or to avoid rejection of bone marrow or organ transplant.

"Nephrotic syndrome" is a kidney disorder that causes the body to pass too much protein in the urine.

"Proteinuria" is when elevated levels of protein are found in the urine.

"Renin-angiotensin system (RAS)" refers to the system of hormones, proteins, enzymes and reactions that help regulate blood pressure. RAS inhibitors include ACE inhibitors and ARBs, as well as direct renin inhibitors.

"Supportive care" is care administered in an attempt to improve quality of life in a person with an illness/disease by preventing or treating the symptoms of the disease and/or the side effects associated with the treatment of the illness/disease.

"Urine-protein-to-creatinine ratio (UPCR)" is a test that measures the amount of protein found in urine.

Clinical Indications

Medical Necessity Criteria for Clinical Review

General Medical Necessity Criteria

The Plan considers Tarpeyo (budesonide delayed release capsules) medically necessary when ALL of the following criteria are met:

1. Prescribed by or in consultation with a nephrologist; *AND*
2. The member has a diagnosis of Immunoglobulin A nephropathy (IgAN) confirmed by kidney biopsy *AND* documentation of ALL of the following:
 - a. is at risk of rapid disease progression; *and*
 - b. glomerular filtration rate (eGFR) is greater than 35 mL/min/1.73 m²; *and*

- c. proteinuria ≥ 1 g/day or UPCR ≥ 0.8 g/g despite at least three months of optimized supportive care consisting of ALL of the following:
 - i. lifestyle modification (such as dietary sodium and protein restriction, smoking cessation, weight control, and exercise as appropriate); *and*
 - ii. maximally tolerated renin-angiotensin system blockade (either an angiotensin-converting enzyme [ACE] inhibitor (e.g., benazepril, enalapril, lisinopril) or angiotensin receptor blocker [ARB] (e.g., candesartan, losartan, valsartan)); *or* the member is unable to use ALL, or has tried and/or failed a maximally tolerated ACE inhibitor or ARB; *AND*
- 3. The member meets ALL of the following:
 - a. No evidence of currently receiving dialysis or has undergone kidney transplant; *or*
 - b. No evidence of presence of other glomerulopathies, such as C3 glomerulopathy or diabetic nephropathy; *or*
 - c. No evidence of nephrotic syndrome, characterized by proteinuria greater than 3.5 g/day, serum albumin levels below 3.0 g/dL, and with or without edema. The only exception to this exclusion criteria is for patients diagnosed with IgA nephropathy accompanied by nephrotic syndrome. In such cases, coverage for the drug may be considered; *or*
 - d. No evidence of previously receiving a treatment course of Tarpeyo (budesonide delayed release capsules); *AND*
- 4. Tarpeyo (budesonide delayed release capsules) will be used as an add-on treatment to optimized standard care including a maximally-tolerated, stable dose of an ACE inhibitor or ARB, unless the member is unable to use ALL ACE inhibitors or ARBs; *AND*
- 5. The member meets ONE of the following:
 - a. The member has tried and failed generic systemic methylprednisolone with or without prednisolone or prednisone, or prednisone, for 6 to 9 months (see [Appendix A](#)); *or*
 - b. The member is unable to use methylprednisolone or prednisone due to an adverse event or contraindication that would NOT exist or be reasonably expected to occur with Tarpeyo (budesonide delayed release capsules); *AND*
- 6. Tarpeyo (budesonide delayed release capsules) will be dosed within the manufacturer's published dosing guidelines or falls within dosing guidelines found in a compendia of current literature; *AND*
- 7. Recent (within the last 3 months) chart documentation and supporting laboratory test results are provided for review to substantiate the above listed requirements.

If the above prior authorization criteria are met, Tarpeyo (budesonide delayed release capsules) will be approved for a single 42 weeks (9-months and 2-weeks) treatment course.

Experimental or Investigational / Not Medically Necessary

Tarpeyo (budesonide delayed release capsules) for any other indication is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, or unproven. Non-covered indications include, but are not limited to, the following:

- Autoimmune hepatitis; *or*
- Crohn disease; *or*
- Eosinophilic esophagitis; *or*
- Graft-versus-host disease; *or*
- Microscopic (lymphocytic and collagenous) colitis; *or*
- Pouchitis; *or*
- Refractory celiac disease types 1 and 2; *or*
- Ulcerative colitis; *or*
- Subsequent courses of Tarpeyo after the initial treatment course as safety and efficacy of treatment with subsequent courses have not been established.

References

1. Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NeflgArd Trial Investigators. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NeflgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. *Kidney Int.* 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. PMID: 36270561.
2. Barratt J, Floege J. SGLT-2 inhibition in IgA nephropathy: the new standard of care? *Kidney Int* 2021;100:24-26.
3. Campbell KN. Oral Glucocorticoids for IgA Nephropathy. *JAMA* 2022; 327:1872.
4. Canney M, Barbour SJ, Zheng Y, et al. Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy. *J Am Soc Nephrol* 2021; 32:436.
5. Cattran DC, Appel GB, Coppo R. IgA nephropathy: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <http://www.uptodate.com>.
6. Cleveland Clinic - Renin-angiotensin-aldosterone system (RAAS). Available at: <https://my.clevelandclinic.org/health/articles/24175-renin-angiotensin-aldosterone-system-raas>. Last updated 13 Sep 2022. Accessed 6 Feb 2025.
7. Fellström BC, Barratt J, Cook H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. *Lancet* 2017.
8. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. (KDIGO). IgAN IgAV Public Review Draft. Available at: <https://kdigo.org/igan-igav-public-review-draft/>. Accessed August 14, 2025.
9. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. *Kidney Int* 2021; 100:S1.
10. Lv J, Wong MG, Hladunewich MA, et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. *JAMA* 2022;327:1888-1898.
11. Rovin BH, Barratt J, Heerspink HJL, et al,. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled,

- phase 3 trial. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3.
12. National Cancer Institute - Supportive Care. Available at: <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/supportive-care>. Accessed 6 Feb 2025.
 13. National Cancer Institute - Immunosuppressive agent. Available at <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/immunosuppressive-agent>. Access 7 Feb 2025.
 14. National Organization for Rare Disorders (NORD) Rare Disease Database. IgA Nephropathy. Available at: <https://rarediseases.org/rare-diseases/iga-nephropathy/>. Updated July 19, 2018. Accessed February 24, 2022.
 15. Smith RJH, Appel GB, Blom AM. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol. 2019 Mar; 15(3): 129-143. doi:10.1038/s41581-018-0107-2.
 16. Tarpeyo (budesonide) [prescribing information]. Stockholm Sweden: Colliditas Therapeutics AB; June 2024.
 17. UptoDate. IgA nephropathy: Treatment and prognosis. Available at: <https://www.uptodate.com/contents/iga-nephropathy-treatment-and-prognosis>. Accessed August 14, 2025.
 18. Vaz de Castro PAS, Bitencourt L, Pereira BWS, et al. Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children. Pediatr Nephrol 2022; 37:499.
 19. Wheeler D.C., et al.: A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy . Kidney Int 2021; 100 (1): pp. 215-224.
 20. Wimbury D, Muto M, Bhachu JS, Scionti K, Brown J, Molyneux K, Seikrit C, Maixnerová D, Pérez-Alós L, Garred P, Floege J, Tesař V, Fellstrom B, Coppo R, Barratt J. Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial. Kidney Int. 2024 Feb;105(2):381-388.
 21. Yaghoubi M, Jiang H, Casciano R, Ngai C, Patel M. Cost-effectiveness analysis of targeted-release formulation of budesonide (Tarpeyo) in conjunction with optimized renin-angiotensin system inhibitor (RASi) therapy relative to optimized RASi therapy alone for adults with primary immunoglobulin A nephropathy in the United States. J Manag Care Spec Pharm. 2025 May;31(5):499-509.
 22. Zhang H, Rizk DV, Perkovic V, et al,. Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney Int. 2024 Jan;105(1):189-199. doi: 10.1016/j.kint.2023.09.027. Epub 2023 Oct 31.

Appendix A

Table 1: Recommended Dosing and duration of glucocorticoid therapy for adult patients with IgA nephropathy

Glucocorticoid	Initial dose	Duration of initial dose	Taper	Total duration of glucocorticoid therapy
Methylprednisolone (IV)	Methylprednisolone 1 g IV for 3 days at the start	6 months	None	6 months

Glucocorticoid	Initial dose	Duration of initial dose	Taper	Total duration of glucocorticoid therapy
and Prednisolone/prednisone (oral)	of months 1, 3, and 5 and Prednisolone or prednisone 0.5 mg/kg orally every other day on remaining days			
Prednisone	1 mg/kg orally per day (maximum dose: 75 mg/day)	2 months	Reduce daily dose by 0.2 mg/kg every month for 4 months	6 months
Prednisone	0.8 to 1 mg/kg orally per day	2 months	Reduce daily dose by 5 to 10 mg every 2 weeks for ≥ 4 months	6 to 8 months
Methylprednisolone	0.4 mg/kg orally once daily (rounded to nearest 4 mg; maximum dose: 32 mg/day)	2 months	Reduce daily dose by 4 mg every month for ≥ 4 months	6 to 9 months
Tarpeyo (budesonide) delayed release capsules	16 mg orally daily	9 months	Reduce dose to 8 mg once daily for 2 weeks, then discontinue	9 months and 2 weeks

Clinical Guideline Revision / History Information

Original Date: 03/17/2022

Reviewed/Revised: 3/23/2023, 3/21/2024, 7/1/2025, 01/01/2026

